PA-WESTINGHOUSE-ELECTRIC
22.2.2024 10:01:28 CET | Business Wire | Press release
Westinghouse organized the 5th annual VVER Fuel Forum in Bratislava with representatives from six utilities. The forum, hosted by Slovenské elektrárne, provided the opportunity to share experiences and best practices with VVER-1000 and VVER-440 fuel deployment in operating reactors.
Westinghouse offered detailed briefings on fuel licensing, NOVA E-6 design enhancements, fabrication plant upgrades, delivery and operations.
As the leader of the European Union-funded APIS project (Accelerated Program for Implementation of secure VVER fuel Supply), Westinghouse also presented additional information on next-generation fuel design development and a harmonized approach for VVER fuel licensing.
“We are pleased to host so many colleagues in Bratislava to discuss the critical topic of fuel diversification,” said Branislav Strýček, Chairman of the Board of the Board of Directors and General Director of Slovenské elektrárne. “We are currently going through the preparation of the documentation in Slovakia for new VVER-440 fuel and expect to finish the licensing process by 2026-2027. We are looking forward to achieving diversification of fuel sources as we expand the lifetime operations of our nuclear plants.”
“In Ukraine, we started the licensing process for the Westinghouse VVER-440 fuel in 2022 and, thanks to great cooperation, we successfully completed it within 1.5 years. We received the first fuel load for Rivne unit 2 last September, ahead of the originally planned schedule. Our two units will be operating later this year with the new fuel, which has been performing well after six months," said Olexandr Depenchuk, Director for Nuclear and Radiation Safety of Energoatom. “The joint efforts of Energoatom and Westinghouse have enabled us to end our dependence on Russian fuel.”
“We recommend expediting the ongoing fuel diversification efforts in the context of the REPowerEU Plan launched in May 2022 and the global energy disruption caused by Russia’s invasion of Ukraine,” said Stefano Ciccarello, Acting Director General of the Euratom Supply Agency.
In Finland, Fortum is pursuing mechanical operating experiences with the new fuel type, after a test assembly manufactured by Westinghouse was loaded into the Loviisa-2 reactor last year. “The changes done in the design of the VVER-440 fuel we originally used in Loviisa in the early 2000s improved the fuel behavior and performance. We are currently reviewing the licensing and manufacturing documentation of the first new fuel deliveries and expect this work to be ready this summer,” said Iiro-Ville Lehtinen, Fortum Project Manager.
“Westinghouse will deliver the first batch of VVER-440 fuel assemblies to the Dukovany nuclear power plant at the end of this year. The deliveries for Temelín will follow a few months after Dukovany, as mutually agreed based on the refueling schedule,” said Rostislav Štaubr, Head of Nuclear Fuel Procurement of CEZ.
“We really appreciate our collaboration with Westinghouse,” said Svilena Nikolova, Head of Legal and Commercial Department of Kozloduy Nuclear Power Plant. “The diversification that has been obtained in terms of nuclear fuel supply is of great importance for the power plant. As Kozloduy celebrates its 50th anniversary this year, we will also receive the first load of new VVER-1000 fuel from Westinghouse for our unit 5.”
“We are delighted to share the achievements of this key program to ensure energy security and supply diversification for our customers in the region,” said Tarik Choho, Westinghouse President of Nuclear Fuel. “There were many great achievements in the past years and still a lot of work ahead of us. As the only European VVER fuel manufacturer, we are committed to delivering what is required by our customers.”
Westinghouse is a leading supplier of nuclear fuel, providing a uniquely diversified portfolio in the industry across nuclear reactor types, including PWR, BWR, AGR and VVER. Through our world-class manufacturing facilities in Sweden, the U.K. and the U.S., we focus on delivering innovative fuel technologies to meet our customers’ needs for lower fuel cycle costs, increased operational flexibility and efficiency, diversity of supply and accident-tolerant products. Learn more about our advanced fuel capabilities and how they relate to different reactors around the world: Westinghouse Nuclear > Nuclear Fuel.
Westinghouse Electric Company is shaping the future of carbon-free energy by providing safe, innovative nuclear technologies to utilities globally. Westinghouse supplied the world’s first commercial pressurized water reactor in 1957 and the company’s technology is the basis for nearly one-half of the world's operating nuclear plants. Over 135 years of innovation make Westinghouse the preferred partner for advanced technologies covering the complete nuclear energy life cycle. For more information, visit www.westinghousenuclear.com and follow us on Facebook, LinkedIn and X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240222283969/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
